Treatment of localized oral MALT lymphoma by rituximab: a case report.
BACKGROUND
Extranodal marginal zone B cell lymphoma of mucosa-associated lymphoma tissue (MALT) among intraoral malignant lymphomas is very rare. Moreover, no case of oral MALT lymphoma treated with monoclonal antibody therapy has been reported.


CONCLUSIONS
We describe a case of MALT lymphoma arising in an 87-year-old Japanese woman under the buccal mucosa that was successfully treated with rituximab, a chimeric monoclonal antibody against the B cell-specific antigen CD20. Currently, 5 months after completing treatment, the patient is alive and has partial regression of the tumor.
Yamagata
Kenji
K
Department of Oral and Maxillofacial Surgery, Institute of Clinical Medicine, University of Tsukuba, 1-1-1 Tennodai, Tsukuba, Ibaraki, Japan. y-kenji@md.tsukuba.ac.jp
Onizawa
Kojiro
K
Kojima
Hiroshi
H
Yoshida
Hiroshi
H
D000369:Aged, 80 and over; D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D058846:Antibodies, Monoclonal, Murine-Derived; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D007155:Immunologic Factors / Q000627:therapeutic use*; D007167:Immunotherapy; D018442:Lymphoma, B-Cell, Marginal Zone / Q000188:drug therapy*; D009062:Mouth Neoplasms / Q000188:drug therapy*; D000069283:Rituximab
D000911:Antibodies, Monoclonal; D058846:Antibodies, Monoclonal, Murine-Derived; D000970:Antineoplastic Agents; D007155:Immunologic Factors; D000069283:Rituximab